drugset / Trial / NCT01149824
Placebo Controlled Study of Sublingual Salvinorin A
NaSingle-groupSingle-blind
Summary
In this study, our aim is to determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. This study is an ascending-dose, placebo-controlled, single-site design in 8 Salvia-experienced subjects. Subjects will receive SA doses from 0-4000 µg. Doses will be separated by at least one day. The first two doses (0 and 100µg) will be double-blinded while the last four (250, 500, 1000, 2000 and 4000µg) will be single-blind.
Timeline
- Start
- 2009-06
- Primary completion
- 2009-12
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Salvinorin A | Small molecule | 100 ug | Subcutaneous |
| Subject | Salvinorin A | Small molecule | 250 ug | Subcutaneous |
| Subject | Salvinorin A | Small molecule | 500 ug | Subcutaneous |
| Subject | Salvinorin A | Small molecule | 1000 ug | Subcutaneous |
| Subject | Salvinorin A | Small molecule | 2000 ug | Subcutaneous |
| Subject | Salvinorin A | Small molecule | 4000 ug | Subcutaneous |
Indications
No indication recorded.